Chemopreventive activity of selenocysteine prodrugs against tobacco-derived nitrosamine (NNK) induced lung tumors in the A/J mouse

Journal of Biochemical and Molecular Toxicology

Volumn 19, Issue 6, 2006, Pages 396-405

  Li, Liang ^a   Xie, Yang ^a   El Sayed, Wael M ^a   Szakacs, Juliana G ^b   Franklin, Michael R ^a   Roberts, Jeanette C ^a,c  

^a UNIVERSITY OF UTAH   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

Cancer Chemoprevention; Prodrugs; Selenazolidines; Selenium; Selenocysteine

Indexed keywords

4 (METHYLNITRAMINO) 1 (3 PYRIDYL) 1 BUTANONE; CARBOXYLIC ACID DERIVATIVE; GLUTATHIONE PEROXIDASE; NITROSAMINE; PRODRUG; SELENIUM; SELENIUM METHYL SELENOCYSTEINE; SELENOCYSTEINE; SELENOMETHIONINE; SODIUM SELENITE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER PREVENTION; CONTROLLED STUDY; DIET SUPPLEMENTATION; DRUG EFFICACY; ENZYME ACTIVITY; ERYTHROCYTE; FEMALE; LIVER LEVEL; LUNG ADENOMA; LUNG CANCER; LUNG CARCINOGENESIS; MOUSE; NONHUMAN; TOBACCO; TREATMENT OUTCOME;

ANIMALIA; NICOTIANA TABACUM;

EID: 31344439400     PISSN: 10956670     EISSN: 10990461     Source Type: Journal    
DOI: 10.1002/jbt.20105     Document Type: Article

References (79)

1. Jemal A, Clegg LX, Ward E, Ries LA, Wu X, Jamison, PM, Wingo PA, Howe HL, Anderson RN, Edwards BK. Annual report to the nation on the status of cancer, 1975-2001, with a special feature regarding survival. Cancer 2004;101:3-27.
2. American Cancer Society. Cancer facts & figures 2005. Available at www.cancer.org/downloads/STT/CAFF2005f4PWSecured.pdf. Accessed on April 4, 2005.
3. National Cancer Institute. Lung cancer information. Available at http://www.nci.nih.gov/cancertopics/types/lung. Accessed on April 4, 2005.
4. Jemal A, Thomas A, Murray T, Thun M. Cancer statistics. CA Cancer J Clin 2002;52:23-47.
5. Scheid P, Vignaud JM, Martinet N, Martinet Y. Chemoprevention perspectives for bronchial cancer. Rev Pneumol Clin 2001;57:193-199.
6. Hoffmann D, Djordjevic MV, Fan J, Zang E, Glynn T, Connolly GN. Five Leading U.S. commercial brands of Moist snuff in 1994; assessment of carcinogenic N-nitrosamines. J Natl Cancer Inst 1995;87:1862-1869.
7. Wynder EL. The past, present, and future of the prevention of lung cancer. Cancer Epidemiol Biomarkers Prev 1998;7:735-748.
8. Omenn GS. Human lung cancer chemoprevention strategies: Parker B. Francis lecture. Chest 2004;125:123S-127S.
9. Hoffmann D, Hoffmann I, El-Bayoumy K. The less harmful cigarette: A controversial issue. A tribute to Ernst L. Wynder. Chem Res Toxicol 2001;14:767-790.
10. Hecht SS. Cigarette smoking and lung cancer: Chemical mechanisms and approaches to prevention. Lancet Oncol 2002;3:461-469.
11. Murrah VA, Gilchrist EP, Moyer MP. Morphologic and growth effects of tobacco-associated chemical carcinogens and smokeless tobacco extracts on human oral epithelial cells in culture. Oral Surg Oral Med Oral Pathol 1993;75:323-332.
12. Brunnemann KD, Prokopczyk B, Kjordjevic MV, Hoffmann D. Formation and analysis of tobacco-specific N-nitrosamines. Crit Rev Toxicol 1996;26:121-137.
13. Chhabra SK, Souliotis VL, Kyrtopoulos SA, Anderson LM. Nitrosamines, alcohol, and gastrointestinal tract cancer: Recent epidemiology and experimentation. In Vivo 1996;10:265-284.
14. Hecht SS. Biochemistry, biology, and carcinogenicity of tobacco-specific N-nitrosamines. Chem Res Toxicol 1998;11:560-603.
15. Peterson LA, Thomson NM, Crankshaw DL, Donaldson EE, Kenney PJ. Interactions between methylating and pyridyloxobutylating agents in A/J mouse lungs: Implications for 4-(methylnitrosamino)-1-(3-pyridyI)-1-butanone-induced lung tumorigenesis. Cancer Res 2001;61:5757-5763.
16. Adams JD, Lee SJ, Vinchkoski N, Castonguay A, Hoffmann D. On the formation of the tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl) -1-butanone during smoking. Cancer Lett 1983;17:339-346.
17. Fischer S, Spiegelhalder B, Eisenbarth, J, Preussmann R. Investigations on the origin of tobacco-specific nitrosamines in mainstream smoke of cigarettes. Carcinogenesis 1990;11:723-730.
18. El-Bayoumy K, Upadhyaya P, Desai DH, Amin S, Hecht SS. Inhibition of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone tumorigenicity in mouse lung by the synthetic organoselenium compound, 1,4-phenylenebis(methylene)selenocyanate. Carcinogenesis 1993;14:1111-1113.
19. Prokopczyk B, Amin S, Desai DH, Kurtzke C, Upadhyaya P, El-Bayoumy K. Effects of 1,4-phenylenebis(methylene)selenocyanate and selenomethionine on 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced tumorigenesis in A/J mouse lung. Carcinogenesis 1997;18:1855-1857.
20. Taylor PR, Albanes D. Selenium, vitamin E, and prostate cancer-Ready for prime time? J Natl Cancer Inst 1998;90:1184-1185.
21. Nelson MA, Porterfield BW, Jacobs ET, Clark LC. Selenium and prostate cancer prevention. Semin Urol Oncol 1999;17:91-96.
22. Menter DG, Sabichi AL, Lippman SM. Selenium effects on prostate cell growth. Cancer Epidemiol Biomarkers Prev 2000;9:1171-1182.
23. Nomura AM, Lee J, Stemmermann GN, Combs GF Jr. Serum selenium and subsequent risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2000;9:883-887.
24. Witschi H. Successful and not so successful chemoprevention of tobacco smoke-induced lung tumors. Exp Lung Res 2000;26:743-755.
25. Costello AJ. A randomized, controlled chemoprevention trial of selenium in familial prostate cancer: Rationale, recruitment, and design issues. Urology 2001;57:182-184.
26. Kelloff GJ, Lieberman R, Steele VE, Boone CW, Lubet RA, Kopelovich L, Malone WA, Crowell JA, Higley HR, Sigman CC. Agents, biomarkers, and cohorts for chemopreventive agent development in prostate cancer. Urology 2001;57:46-51.
27. Cohen V, Khuri FR. Chemoprevention of lung cancer. Curr Opin Pulm Med 2004;10:279-283.
28. Blot WJ, Li J-Y, Taylor PR, Guo W, Dawsey S, Wang G-Q, Yang, CS, Zheng SF, Gail M, Li G-Y, Yu Y, Liu B-q, Tangrea J, Sun Y-h, Liu F, Fraumeni JF Jr, Zhang Y-H, Li B. Nutrition intervention trials in Linxian, China: Supplementation with specific vitamin/mineral combinations, cancer incidence, and disease-specific mortality in the general population. J Natl Cancer Inst 1993;85:1483-1492.
29. Clark LC, Combs GF Jr, Turnbull BW, Slate EH, Chalker, DK, Chow J, Davis LS, Glover RA, Graham GF, Gross EG, Krongrad A, Lesher JL Jr, Park HK, Sanders BB Jr, Smith CL, Taylor JR. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. JAMA 1996;276:1957-1963.
30. Gonzalez PM, Benner SE. Clinical studies in head and neck cancer chemoprevention. Cancer Metastasis Rev 1996;15:113-118.
31. Hercberg S, Preziosi P, Galan P, Faure H, Arnaud J, Duport N, Malvy D, Roussel AM, Briancon S, Favier A. "The SU. VI.MAX study": A primary prevention trial using nutritional doses of antioxidant vitamins and minerals in cardiovascular diseases and cancers. Supplementation on Vitamines et Mineraux AntioXydants. Food Chem Toxicol 1999;37:925-930.
32. Clark LC, Marshall JR, Randomized, controlled chemoprevention trials in populations at very high risk for prostate cancer: Elevated prostate-specific antigen and high-grade prostatic intraepithelial neoplasia. Urology 2001;7:185-187.
33. Hoque A, Albanes D, Lippman SM, Spitz, MR, Taylor PR, Klein EA, Thompson IM, Goodman P, Stanford JL, Crowley JJ, Coltman CA, Santella RM. Molecular epidemiologic studies within the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Cancer Causes Control 2001;12:627-633.
34. Galan P, Favier A, Preziosi P, Bertrais S, Arnault N, Hercberg S. The bank of biological material in the SU.VI.MAX study. Rev Epidemiol Sante Publique 2003;51:147-150.
35. Klein EA, Thompson IM. Update on chemoprevention of prostate cancer. Curr Opin Urol 2004;14:143-149.
36. Meuillet E, Stratton S, Prasad Cherukuri D, Goulet AC, Kagey J, Porterfield B, Nelson MA. Chemoprevention of prostate cancer with selenium: An update on current clinical trials and preclinical findings. J Cell Biochem 2004;91:443-458.
37. Xie Y, Short MD, Cassidy PB, Roberts JC. Selenazolidines as novel organoselenium delivery agents. Bioorg Med Chem Lett 2001;11:2911-2915.
38. Short MD, Xie Y, Li L, Cassidy PB, Roberts JC. Characteristics of selenazolidine prodrugs of selenocysteine: Toxicity and glutathione peroxidase induction in V79 cells. J Med Chem 2003;46:3308-3313.
39. Nagasawa HT, Goon DJW, Zera RT, Yuzon DL. Prodrugs of L-cysteine as liver-protective agents. 2(RS)-Methylthiazolidine-4(R)-carboxylic acid, a latent cysteine. J Med Chem 1982;25:489-491.
40. Roberts JC, Nagasawa HT, Zera RT, Fricke RF, Goon DJW. Prodrugs of L-cysteine as protective agents against acetaminophen-induced hepatotoxicity. 2-(Polyhydroxyalkyl)- and 2-(polyacetoxyalkyl)thiazolidine-4(R)-carboxylic acids. J Med Chem 1987;30:1891-1896.
41. Li L, Xie Y, El-Sayed WM, Szakacs JG, Roberts JC. Characteristics of selenazolidine prodrugs of selenocysteine: Toxicity, selenium levels, and glutathione peroxidase induction in A/J mice. Life Sci 2004;75:447-459.
42. Shimkin MB, Stoner GD. Lung tumors in mice: Application to carcinogenesis bioassay. Adv Cancer Res 1975;21:1-58.
43. Hecht SS, Hoffmann D. Tobacco-specific nitrosamines, an important group of carcinogens in tobacco and tobacco smoke. Carcinogenesis 1988;9:875-884.
44. Hecht SS, Morse MA, Eklind KI, Chung FL. A/J mouse lung tumorigenesis by the tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone and its inhibition by arylalkyl isothiocyanates. Exp Lung Res 1991;17:501-511.
45. Belinsky SA, Stefanski SA, Anderson MW. The A/J mouse lung as a model for developing new chemointervention strategies. Cancer Res 1993;53:410-416.
46. El-Bayoumy K, Upadhyaya P, Desai, DH, Amin S, Hoffmann D, Wynder EL. Effects of 1,4-phenylenebis(methylene)selenocyanate, phenethyl isothiocyanate, indole-3-carbinol, and d-limonene individually and in combination on the tumorigenicity of the tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3- pyridyl)-1-butanone in A/J mouse lung. Anticancer Res 1996;16:2709-2712.
47. Wattenberg LW, Wiedmann TS, Estensen RD, Zimmerman CL, Galbraith AR, Steele VE, Kelloff GJ. Chemoprevention of pulmonary carcinogenesis by brief exposures to aerosolized budesonide or beclomethasone dipropionate and by the combination of aerosolized budesonide and dietary myo-inositol. Carcinogenesis 2000;21:179-182.
48. Witschi H. A/J mouse as a model for lung tumorigenesis caused by tobacco smoke: strengths and weaknesses. Exp Lung Res 2005;31:3-18.
49. Ganther HE. Selenium metabolism, selenoproteins and mechanism of cancer prevention: Complexities with thioredoxin reductase. Carcinogenesis 1999;20:1657-1666.
50. Ip C, Thompson HJ, Zhu Z, Ganther HE. In vitro and in vivo studies of methylseleninic acid: Evidence that a monomethylated selenium metabolite is critical for cancer chemoprevention. Cancer Res 2000;60:2882-2886.
51. Medina D, Thompson H, Ganther H, Ip C. Se-Methylselenocysteine: A new compound for chemoprevention of breast cancer. Nutr Cancer 2001;40:12-17.
52. Sinha R, Unni E, Ganther HE, Medina D. Methylseleninic acid, a potent growth inhibitor of synchronized mouse mammary epithelial tumor cells in vitro. Biochem Pharmacol 2001;61:311-317.
53. Spallholz JE, Palace VP, Reid TW. Methioninase and selenomethionine but not Se-methylselenocysteine generate methylselenol and superoxide in an in vitro chemiluminescent assay: Implication for the nutritional carcinostatic activity of selenoamino acids. Biochem Pharmacol 2004;67:547-554.
54. Unni E, Kittrell FG, Singh Y, Sinha R. Osteopontin is a potential target gene in mouse mammary cancer chemoprevention by Se-methylselenocysteine. Breast Cancer Res 2004;6:R586-592.
55. Hecht SS, Morse MA, Amin S, Stoner GD, Jordan KG, Choi CI, Chung FL. Rapid single-dose model for lung tumor induction in A/J mice by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone and the effect of diet. Carcinogenesis 1989;10:1901-1904.
56. Malkinson AM, Beer DS. Major effect on susceptibility to urethane-induced pulmonary adenoma by a single gene in BALB/cBy mice. J Natl Cancer Inst 1983;70:931-936.
57. Sohn OS, Blackwell L, Mathis J, Asaad WW, Reddy BS, El-Bayoumy K. Excretion and tissue distribution of selenium following treatment of male F344 rats with benzylselenocyanate or sodium selenite. Drug Metab Dispos 1991;19:865-870.
58. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248-254.
59. Paglia DE, Valentine WN. Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase. J Lab Clin Med 1967;70:158-169.
60. Malkinson AM. Primary lung tumors in mice: an experimentally manipulable model of human adenocarcinoma. Cancer Res 1992;52:2670s-2676s.
61. Smith TJ, Yang GY, Seril DN, Liao J, Kim S. Inhibition of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced lung tumorigenesis by dietary olive oil and squalene. Carcinogenesis 1998;19:703-706.
62. Goralczyk R, Wertz K, Lenz B, Riss G, Buchwald Hunziker P, Geatrix B, Aebischer CP, Bachmann H. Beta-carotene interaction with NNK in the AJ-mouse model: Effects on cell proliferation, tumor formation and retinoic acid responsive genes. Biochim Biophys Acta 2005;1740:179-188.
63. Beilstein MA, Whanger PD. Chemical forms of selenium in rat tissues after administration of selenite or selenomethionine. J Nutr 1986;116:1711-1719.
64. Deagen JT, Butler JA, Beilstein, MA, Whanger PD. Effects of dietary selenite, selenocystine and selenomethionine on selenocysteine lyase and glutathione peroxidase activities and on selenium levels in rat tissues. J Nutr 1987;117:91-98.
65. Lane HW, Medina D, Wolfe LG. Proposed mechanisms for selenium-inhibition of mammary tumorigenesis. In Vivo 1989;3:151-160.
66. Koyama H, Omura K, Ejima A, Kasanuma Y, Watanabe C, Satoh H. Separation of selenium-containing proteins in human and mouse plasma using tandem high-performance liquid chromatography columns coupled with inductively coupled plasma-mass spectrometry. Anal Biochem 1999;267:84-91.
67. Burk RF, Hill KE, Motley AK. Plasma selenium in specific and non-specific forms. Biofactors 2001;14:107-114.
68. Weiss SL, Evenson JK, Thompson KM, Sunde RA. The selenium requirement for glutathione peroxidase mRNA level is half of the selenium requirement for glutathione peroxidase activity in female rats. J Nutr 1996;126:2260-2267.
69. Klurfeld DM, Welch CB, Davis MJ, Kritchevsky D. Determination of degree of energy restriction necessary to reduce DMBA-induced mammary tumorigenesis in rats during the promotion phase. J Nutr 1989;119:286-291.
70. Klurfeld DM, Weber MM, Kritchevsky D. Inhibition of chemically induced mammary and colon tumor promotion by caloric restriction in rats fed increased dietary fat. Cancer Res 1987;47:2759-2762.
71. Kritchevsky D, Weber MM, Buck CL, Klurfeld DM. Calories, fat and cancer. Lipids 1986;21:272-274.
72. Kumar SP, Roy SJ, Tokumo K, Reddy BS. Effect of different levels of calorie restriction on azoxymethane-induced colon carcinogenesis in male F344 rats. Cancer Res 1990;50:5761-5766.
73. Pollard M, Luckert PH. Tumorigenic effects of direct- and indirect-acting chemical carcinogens in rats on a restricted diet. J Natl Cancer Inst 1985;74:1347-1349.
74. Roebuck BD, Yager JD Jr, Longnecker DS. Dietary modulation of azaserine-induced pancreatic carcinogenesis in the rat. Cancer Res 1981;41:888-893.
75. Tannenbaum A, Silverstone H. The influence of the degree of caloric restriction on the formation of skin tumors and hepatomas in mice. Cancer Res 1949;9:724-727.
76. Lagopoulos L, Stalder R. The influence of food intake on the development of diethylnitrosamine-induced liver tumours in mice. Carcinogenesis 1987;8:33-37.
77. Pashko LL, Schwartz AG. Inhibition of 7,12-dimethylbenz[a]anthracene- induced lung tumorigenesis in A/J mice by food restriction is reversed by adrenalectomy. Carcinogenesis 1996;17:209-212.
78. Fu PP, Dooley KL, Von Tungeln LS, Bucci T, Hart RW, Kadlubar FF. Caloric restriction profoundly inhibits liver tumor formation after initiation by 6 nitrochrysene in male mice. Carcinogenesis 1994;15:159-161.
79. Kolaja KL, Bunting KA, Klaunig JE. Inhibition of tumor promotion and hepatocellular growth by dietary restriction in mice. Carcinogenesis 1996;17:1657-1664.